NVTR - Nuvectra Corporation

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
9.71
-0.15 (-1.52%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close9.86
Open9.86
Bid0.00 x 1100
Ask0.00 x 800
Day's Range9.60 - 9.97
52 Week Range9.60 - 25.17
Volume155,223
Avg. Volume212,853
Market Cap172.762M
Beta (3Y Monthly)-0.00
PE Ratio (TTM)N/A
EPS (TTM)-3.26
Earnings DateOct 30, 2018 - Nov 5, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.75
Trade prices are not sourced from all markets
  • Are Nuvectra Corporation (NASDAQ:NVTR) Shareholders Getting A Good Deal?
    Simply Wall St.18 days ago

    Are Nuvectra Corporation (NASDAQ:NVTR) Shareholders Getting A Good Deal?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Nuvectra Corporation (NASDAQ:NVTR) shareholders, and potential investors, need to understand how much cash the business makes...

  • ACCESSWIRE20 days ago

    FDA Events Can Send Stocks Soaring: Here's One That No One Is Talking About

    Biogen's (BIIG) latest clinical trial failure is a testament to the difficulty in developing drugs for Alzheimer's, which is littered with failures in the last ten years. But other neurology fields have ...

  • GlobeNewswire28 days ago

    Nuvectra® Appoints Anthony P. Bihl, III as New Chairman of the Board

    Nuvectra Corporation (NVTR), a neurostimulation medical device company, today announced the appointment of Anthony P. Bihl, III as Chairman of the Board of Directors, following Dr. Joseph A. Miller’s retirement from the Board, effective immediately. Concurrently, Jane J. Song was appointed as an independent member of the Company’s Board of Directors and as a member of the Board’s Governance and Nomination Committee. Mr. Bihl stated, “I am honored to enter my new role as Chairman of the Board and welcome Jane, an industry leader, to Nuvectra.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of NVTR earnings conference call or presentation 28-Feb-19 9:30pm GMT

    Q4 2018 Nuvectra Corp Earnings Call

  • GuruFocus.com2 months ago

    Nuvectra Corp (NVTR) Files 10-K for the Fiscal Year Ended on December 31, 2018

    Nuvectra Corp (NASDAQ:NVTR) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018.

  • GlobeNewswire2 months ago

    Nuvectra® Reports Fourth Quarter and Full Year 2018 Financial Results

    PLANO, Texas, Feb. 28, 2019 -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today financial results for the fourth quarter and full.

  • How Financially Strong Is Nuvectra Corporation (NASDAQ:NVTR)?
    Simply Wall St.2 months ago

    How Financially Strong Is Nuvectra Corporation (NASDAQ:NVTR)?

    While small-cap stocks, such as Nuvectra Corporation (NASDAQ:NVTR) with its market cap of US$246m, are popular for their explosive growth, investors should also be aware of their balance sheet toRead More...

  • GlobeNewswire2 months ago

    Nuvectra® to Present at 39th Annual Cowen Healthcare Conference

    PLANO, Texas, Feb. 26, 2019 -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that Fred Parks, PhD, Chief Executive Officer,.

  • Will Nuvectra (NVTR) Report Negative Earnings Next Week? What You Should Know
    Zacks2 months ago

    Will Nuvectra (NVTR) Report Negative Earnings Next Week? What You Should Know

    Nuvectra (NVTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire2 months ago

    The Future Is Now; Med Tech That’s Changing Lives

    Investorideas.com, a leading investor news resource covering medical technology and healthcare stocks releases a snapshot looking at the rapid advancements happening in the med tech sector and how many of these “far off” projects are now on the verge of reality. BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, recently announced that the Company successfully conducted the first patient cases using PURE EP™ System, its FDA approved proprietary signal acquisition and processing technology. The first commercial use of the System was completed at the Texas Cardiac Arrhythmia Institute (“TCAI”) in Austin, TX.

  • GlobeNewswire2 months ago

    Nuvectra to Report Fourth Quarter and Full Year 2018 Financial Results on February 28, 2019

    PLANO, Texas, Feb. 19, 2019 -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that it will release its financial results for.

  • Why Nuvectra Stock Is Cratering Today
    Motley Fool3 months ago

    Why Nuvectra Stock Is Cratering Today

    A sudden change in leadership isn't sitting well with some of Nuvectra's shareholders.

  • GlobeNewswire3 months ago

    Nuvectra® Appoints Dr. Fred B. Parks as Chief Executive Officer

    Nuvectra Corporation (NVTR), a neurostimulation medical device company, today announced the appointment of Fred B. Parks, PhD, as Chief Executive Officer, effective immediately. Dr. Parks has served as a member of the Company’s Board of Directors since March 2016 and will retain his position as a Director.

  • GlobeNewswire3 months ago

    Nuvectra Provides Update on Virtis™ FDA PMA Submission

    Nuvectra Corporation (NVTR), a medical device company dedicated to neuromodulation, announced today that the U.S. Food and Drug Administration (FDA) has advised that its review of Company’s pre-market approval (PMA) application for its Virtis Sacral Neuromodulation (SNM) system has been extended beyond the expiration of the FDA’s 180-day review period. Scott Drees, Chief Executive Officer, commented, “FDA has informed us that they have not yet concluded their review and as such will require an extension of our 180-day review period. To date, FDA has not identified any additional deficiencies or requested any additional information.

  • GlobeNewswire3 months ago

    Nuvectra® Announces Preliminary Unaudited Fourth Quarter and Full Year 2018 Revenue

    Nuvectra Corporation (NVTR), a neurostimulation medical device company, announced today preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2018. Preliminary unaudited consolidated revenue in the fourth quarter of 2018 is expected to be in the range of $15.3 to $15.7 million, compared to $12.0 million in the fourth quarter of 2017. Preliminary unaudited Algovita revenue in the fourth quarter of 2018 is expected to be in the range of $13.6 to $14.1 million, compared to $10.4 million in the fourth quarter of 2017.

  • GlobeNewswire4 months ago

    Nuvectra Announces Divesture of NeuroNexus Subsidiary

    Nuvectra Corporation (NVTR), a neurostimulation medical device company, announced today that it has entered into an agreement effective December 31, 2018, to sell its wholly owned subsidiary NeuroNexus Technologies, Inc. (“NeuroNexus”) to NEL Group, Inc., an entity affiliated with certain former employees of NeuroNexus, for $5.0 million in cash. This press release contains "forward-looking statements," including statements we make regarding the outlook for Nuvectra as an independent publicly-traded company.

  • Could The Nuvectra Corporation (NASDAQ:NVTR) Ownership Structure Tell Us Something Useful?
    Simply Wall St.4 months ago

    Could The Nuvectra Corporation (NASDAQ:NVTR) Ownership Structure Tell Us Something Useful?

    A look at the shareholders of Nuvectra Corporation (NASDAQ:NVTR) can tell us which group is most powerful. Institutions often own shares in more established companies, while it's not unusual to Read More...

  • Here is What Hedge Funds Think About Nuvectra Corporation (NVTR)
    Insider Monkey4 months ago

    Here is What Hedge Funds Think About Nuvectra Corporation (NVTR)

    Hedge funds and other investment firms that we track manage billions of dollars of their wealthy clients’ money, and needless to say, they are painstakingly thorough when analyzing where to invest this money, as their own wealth depends on it. Regardless of the various methods used by elite investors like David Tepper and Dan Loeb, […]

  • GlobeNewswire5 months ago

    Nuvectra Completes 3,000 U.S. Algovita® SCS Implantations

    Nuvectra Corporation (NVTR), a neurostimulation medical device company, announced today that the Company’s Algovita® Spinal Cord Stimulation (SCS) system has been implanted in over 3,000 patients in the U.S. The Algovita system utilizes patent-protected stretchable lead technology with a robust internal pulse generator to deliver four stimulation modes to patients for non-pharmaceutical relief of pain. Scott Drees, Chief Executive Officer, commented, “We are excited to achieve another significant U.S. commercial milestone with the 3,000th implantation of the Algovita system. Nuvectra® is a neurostimulation company committed to helping physicians improve the lives of people with chronic conditions.

  • GlobeNewswire5 months ago

    Nuvectra Receives FDA Head-Only MR-Conditional Approval for Algovita®

    Nuvectra Corporation (NVTR), a neurostimulation medical device company, announced today that it has received U.S. Food and Drug Administration (FDA) head-only MR-conditional approval for the Company’s Algovita SCS system. Scott Drees, Chief Executive Officer, commented, “This FDA approval represents our continued commitment to the advancement of the Algovita system and further enhances our competitive positioning. Nuvectra® is a neurostimulation company committed to helping physicians improve the lives of people with chronic conditions.

  • ACCESSWIRE5 months ago

    FDA Changes Will Reward Medical Device Innovation: Here’s What Investors Need to Know

    The U.S. FDA plans a major overhaul of how medical devices are regulated and approved in the United States. The changes are intended to keep unsafe products off the market and reward innovation from medical device companies. One medical device ETF has almost tripled the performance of the S&P 500 since its inception.

  • GlobeNewswire5 months ago

    New Research Coverage Highlights National American University, Moog, TCP Capital, TriplePoint Venture Growth BDC, Occidental Petroleum, and Nuvectra — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, Nov. 13, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Thomson Reuters StreetEvents6 months ago

    Edited Transcript of NVTR earnings conference call or presentation 29-Oct-18 8:30pm GMT

    Q3 2018 Nuvectra Corp Earnings Call

  • GlobeNewswire6 months ago

    Nuvectra® to Participate in Two Upcoming Investor Conferences

    PLANO, Texas, Oct. 31, 2018 -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that Scott Drees, Chief Executive Officer, and.

  • Nuvectra (NVTR) Reports Q3 Loss, Tops Revenue Estimates
    Zacks6 months ago

    Nuvectra (NVTR) Reports Q3 Loss, Tops Revenue Estimates

    Nuvectra (NVTR) delivered earnings and revenue surprises of -1.16% and 14.88%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?